Under the Radar, page-175

No risk ... no reward

I’d like to see the treatments turn into something, but not at a cost of risking value to share holders.

The commentary from patients using the treatment (non-placebo) on the study was positive. From what I recall the results were on par with an American peer although with a very small sample size, testing safety not cure. Upping dosage could prove to lift above the competition. The American along with the global population has seen the disease rise in recent years

Main concern I have is that it didn’t seem like Wayne explained the results well from the last immunotherapy test.